When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
ARC Document Solutions
The Trade: ARC Document Solutions, Inc. ARC Chairman, President and CEO Kumarakulasingam Suriyakumar acquired a total of 51492 shares at an average price of $2.75. The insider spent $141,781.49 to buy those shares.
What’s Happening: ARC Document Solutions is expected to report Q3 results on November 4, 2021.
What ARC Document Solutions Does: ARC Document Solutions Inc is a global document solutions provider. The company's service offerings include managed print services (MPS), offsite services, archive and information management ( AIM), specialized color printing, Web-based document management applications, and equipment and supplies sales.
DIRTT Environmental Solutions
The Trade: DIRTT Environmental Solutions Ltd. DRTT 10% owner Aron English acquired a total of 133604 shares shares at an average price of $3.09. The insider spent $412,951.37 to buy those shares.
What’s Happening: DIRTT is scheduled to released quarterly results on November 3, 2021.
What DIRTT Environmental Solutions Does: Dirtt Environmental Solutions Ltd is a manufacturer of customized interiors. The company combines its (3D) design, configuration, and manufacturing software (ICE or ICE Software) with in-house manufacturing of its prefabricated interior construction solutions and a distribution partner (DP) network.
The Trade: Eyenovia, Inc. EYEN Chief Operating Officer Michael M Rowe acquired a total of 1200 shares at an average price of $4.14. To acquire these shares, it cost $4,968.00.
What’s Happening: Eyenovia 8-K showed the company sees reporting $21.4 million in cash, cash equivalents as of September 30, 2021.
What Eyenovia Does: Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its propriety array print (MAP) platform technology.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.